Graves’ Disease and Periodic Paralysis

Authors

  • Swayamsidha Mangaraj Senior Resident, Dept. of Endocrinology,S.C.B Medical College, Cuttack, Odisha 753007 India
  • Debarchan Jena Senior Resident, Dept. of Endocrinology,S.C.B Medical College, Cuttack, Odisha 753007 India
  • Pratap Kumar Mishra Senior Resident, Dept. of Endocrinology,S.C.B Medical College, Cuttack, Odisha 753007 India
  • Arun Kumar Choudhury Assistant Professor, Dept. of Endocrinology,S.C.B Medical College, Cuttack, Odisha 753007 India
  • Binoy Kumar Mohanty Associate Professor, Dept. of Endocrinology,S.C.B Medical College, Cuttack, Odisha 753007 India
  • Anoj Kumar Baliarsinha Professor and HOD, Dept. of Endocrinology,S.C.B Medical College, Cuttack, Odisha 753007 India

Keywords:

thyrotoxic periodic paralysis, hypokalemia, Geaves' disease, beta blockers, rebound hyperkalemia, paralysis

Abstract

Thyrotoxic periodic paralysis represents a rare neurological emergency of an endocrine disorder. It poses a diagnostic challenge to the clinicians, as it is an uncommon disorder and its clinical presentation is similar to the more common hypokalemic paralysis. Adding to the diagnostic dilemma is that most patients do not have prior history of thyroid disorder and only have subtle features of hyperthyroidism. Hence, the diagnosis can be easily missed without a high clinical index of suspicion. These patients usually present to the emergency department with acute flaccid paralysis and all physicians should be aware of this clinical entity. The disease can be life-threatening if early diagnosis and prompt therapy is not initiated. We report three interesting cases in which periodic paralysis was the initial manifestation of underlying Graves’ disease in two and occurred in the third case who was previously diagnosed with thyrotoxicosis  due to non-adherence to drug therapy.

Downloads

Download data is not yet available.

References

McFadzean AJ, Yeung R. Periodic paralysis complicating thyrotoxicosis in Chinese. Br Med J. 1967;1:451-455. http://dx.doi.org/10.1136/bmj.1.5538.451.

Rosenfeld M. Akute aufsteigende Lahmungen bei Morbus Basedow. Berl Klin Wochenschr. 1902;39:538-40.

Dunlap HF, Kepler EJ. A syndrome resembling familial periodic paralysis occurring in the course of exolphthalmic goiter. Endocrinology. 1931;15:541-6.

Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med. 1999;159(6):601-606. http://dx.doi.org/10.1001/archinte.159.6.601.

Ko GTC, Chow CC, Yeung VTF, Chan HHL, Li JKY, Cockram CS. Thyrotoxic periodic paralysis in a Chinese population. Q J Med. 1996;89:463-468. http://dx.doi.org/10.1093/qjmed/89.6.463.

Kung AW. Clinical review: Thyrotoxic periodic paralysis: A diagnostic challenge. J Clin Endocrinol Metab.2006;91(7):2490-5. http://dx.doi.org/10.1210/jc.2006-0356.

Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc. 2005;80(1):99-105. http://dx.doi.org/10.4065/80.1.99.

Hsieh MJ, Lyu RK, Chang WN, et al. Hypokalemic thyrotoxic periodic paralysis: Clinical characteristics and predictors of recurrent paralytic attacks. Eur J Neurol. 2008; 15(6):559-564. http://dx.doi.org/10.1111/j.1468-1331.2008.02132.x.

van Dam GM, Reisman Y, van Wieringen K. Hypokalaemic thyrotoxic periodic paralysis: Case report and review of an Oriental syndrome. Neth J Med. 1996; 49(2):90-97. http://dx.doi.org/10.1016/0300-2977(96)00014-9.

Lee KO, Taylor EA, Oh VMS, Cheah JS, Aw SE. Hyperinsulinaemia in thyrotoxic hypokalaemic periodic paralysis. Lancet. 1991;337(8749):1063-1064. http:/dx.doi.org/10.1016/0140-6736(91)91710-C.

Lin SH, Huang CL. Mechanism of thyrotoxic periodic paralysis. J Am Soc Nephrol. 2012; 23: 985-8.

Ryan DP, da Silva MR, Soong TW, Fontaine B, Donaldson MR, Kung AWC, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell. 2010;140(1):88-98. http://dx.doi.org/10.1016/j.cell.2009.12.024.

Maciel RM, Lindsey SC and Dias da Silva MR. Novel etiopathophysiological aspects of thyrotoxic periodic paralysis. Nat Rev Endocrinol. 2011;7:657-667. http://dx.doi.org/10.1038/nrendo.2011.58.

Cheung CL, Lau KS, Ho AY, Lee KK, Tiu SC, Lau EY, et al. Genome-wide association study identifies a susceptibility locus for thyrotoxic periodic paralysis at 17q24.3. Nature Genetics. 2012;44:1026-1029. http://dx.doi.org/10.1038/ng.2367.

Jongjaroenprasert W, Phusantisampan T, Mahasirimongkol S, Mushiroda T, Hirankarn N, Snabboon T, et al. A genome-wide association study identifies novel susceptibility genetic variation for thyrotoxic hypokalemic periodic paralysis. J Hum Genet. 2012;57: 301-304. http://dx.doi.org/10.1038/jhg.2012.20.

Chu PY, Cheng CJ, Tseng MH, Yang SS, Chen HC, Lin SH. Genetic variant rs623011 (17q24.3) associates with non-familial thyrotoxic and sporadic hypokalemic paralysis. Clin Chim Acta. 2012;414:105-108. http://dx.doi.org/10.1016/j.cca.2012.08.004.

Chang CC, Cheng CJ, Sung CC, Chiueh TS, Lee CH, Chau T, et al. A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: Focus on symptomatology and precipitants. Eur J Endocrinol. 2013;169:529-36. http://dx.doi.org/10.1530/EJE-13-0381.

Li X, Yao S, Xiang Y, et al. The clinical and genetic features in a cohort of mainland Chinese patients with thyrotoxic periodic paralysis. BMC Neurology. 2015;15:38. http://dx.doi.org/10.1186/s12883-015-0290-8.

Boccalandro C, Lopez L, Boccalandro F, Lavis V. Electrocardiographic changes in thyrotoxic periodic paralysis. Am J Cardiol. 2003;91(6):775-777. http://dx.doi.org/10.1016/S0002-9149(02)03431-8.

Hsu Y, Lin Y, Chau T, Liou JT, Kuo SW, Lin SH. Electrocardiographic manifestations in patients with thyrotoxic periodic paralysis. Am J Med Sci. 2003;326: 128-32.

Lin SH, Lin YF. Propranolol rapidly reverses paralysis, hypokalemia and hypophosphatemia in thyrotoxic periodic paralysis. Am J Kidney Dis. 2001;37(3):620-623. http://dx.doi.org/10.1053/ajkd.2001.22090.

Yeung RT, Tse TF. Thyrotoxic periodic paralysis: Effect of propranolol. Am J Med. 1974;57:584-90.

Cesur M, Bayram F, Temel MA, et al. Thyrotoxic hypokalaemic periodic paralysis in a Turkish population: Three new case reports and analysis of the case series. Clin Endocrinol (Oxf) 2008;68(1):143-152.

http://dx.doi.org/10.1111/j.1365-2265.2007.03014.x.

Tassone H, Moulin A, Henderson SO. The pitfalls of potassium replacement in thyrotoxic periodic paralysis: A case report and review of the literature. J Emerg Med. 2004;26(2):157-161. http://dx.doi.org/10.1016/j.emermed.2003.05.004.

Lu KC, Hsu YJ, Chiu JS, Hsu YD, Lin SH. Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. Am J Emerg Med. 2004;22(7):544-7. http://dx.doi.org/10.1016/j.ajem.2004.09.016.

Chang RY, Lang BH, Chan AC, Wong KP. Evaluating the efficacy of primary treatment for Graves’ disease complicated by thyrotoxic periodic paralysis. Int J Endocrinol. 2014; 2014. Article ID 949068. http://dx.doi.org/10.1155/2014/949068.

Published

2015-11-30

How to Cite

Mangaraj, S., Jena, D., Mishra, P. K., Choudhury, A. K., Mohanty, B. K., & Baliarsinha, A. K. (2015). Graves’ Disease and Periodic Paralysis. Journal of the ASEAN Federation of Endocrine Societies, 30(2), 181. Retrieved from https://asean-endocrinejournal.org/index.php/JAFES/article/view/220

Issue

Section

Case Reports